20 Sep 2008 , Berlin, Germany / Montreal, Canada : New data confirm that early initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) significantly delays the onset of clinically-definite MS (CDMS) by 37 percent (p=0.003) and McDonald MS by 45 percent (p<0.0001) over five years compared to delayed treatment. The results confirm a continued benefit of initiating treatment with Betaferon shortly after the first event. These five year findings from the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) study were presented today at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) in Montreal, Canada.
